Published in Int Immunopharmacol on May 13, 2009
Management of polyomavirus-associated nephropathy in renal transplant recipients. Nat Rev Nephrol (2012) 1.10
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med (2008) 6.60
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med (2016) 5.31
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet (2006) 3.17
Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 2.98
Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis (2011) 2.75
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A (2011) 2.18
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis (2009) 1.99
Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant (2005) 1.84
Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation (2004) 1.80
The C-terminal region of human adipose triglyceride lipase affects enzyme activity and lipid droplet binding. J Biol Chem (2008) 1.80
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis (2010) 1.75
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
Hepatitis E virus and neurologic disorders. Emerg Infect Dis (2011) 1.70
Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. Dev Cell (2012) 1.62
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Oxidized low-density lipoproteins trigger endoplasmic reticulum stress in vascular cells: prevention by oxygen-regulated protein 150 expression. Circ Res (2008) 1.56
Pathological aspects of lipid peroxidation. Free Radic Res (2010) 1.56
Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int (2011) 1.53
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation (2015) 1.52
Engraftment of human T, B and NK cells in CB.17 SCID/beige mice by transfer of human spleen cells. Transpl Immunol (2005) 1.51
A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse. Nat Genet (2005) 1.50
Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol (2013) 1.50
Oxidized low-density lipoprotein-induced apoptosis. Biochim Biophys Acta (2002) 1.48
Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant (2010) 1.48
Morphologic and functional renal impact of acute kidney injury after prolonged hemorrhagic shock in mice. Crit Care Med (2011) 1.48
Anti-human leukocyte antigen immunization after early allograft nephrectomy. Transplantation (2012) 1.47
Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol (2012) 1.46
The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation (2004) 1.44
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology (2010) 1.44
Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation (2010) 1.44
Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43
Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation (2007) 1.41
Determination of plasma unbound fraction of voriconazole in patients treated with a prophylactic or a curative treatment. Ther Drug Monit (2014) 1.40
Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. Am J Kidney Dis (2009) 1.39
Hepatitis E virus strains in rabbits and evidence of a closely related strain in humans, France. Emerg Infect Dis (2012) 1.37
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int (2004) 1.31
Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther (2009) 1.30
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation (2010) 1.28
Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal (2009) 1.28
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl (2010) 1.26
Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol (2013) 1.21
Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol (2010) 1.17
Increased reactive oxygen species production with antisense oligonucleotides directed against uncoupling protein 2 in murine endothelial cells. Biochem Cell Biol (2002) 1.15
OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation (2013) 1.14
Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis (2004) 1.14
Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections. Clin Vaccine Immunol (2009) 1.13
Structural modifications of HDL and functional consequences. Atherosclerosis (2005) 1.13
Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis (2011) 1.13
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation (2003) 1.13
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation (2011) 1.13
Long-term prospective population PK study in GIST patients--letter. Clin Cancer Res (2013) 1.12
Two distinct calcium-dependent mitochondrial pathways are involved in oxidized LDL-induced apoptosis. Arterioscler Thromb Vasc Biol (2004) 1.12
Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler Thromb Vasc Biol (2002) 1.11
Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant (2004) 1.11
Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother (2010) 1.10
Detection of intracellular reactive oxygen species in cultured cells using fluorescent probes. Methods Enzymol (2002) 1.09
Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med (2006) 1.09
FTY720 (fingolimod) in renal transplantation. Clin Transplant (2006) 1.09
Hepatitis E virus quasispecies and the outcome of acute hepatitis E in solid-organ transplant patients. J Virol (2012) 1.09
Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis (2004) 1.09
Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant (2005) 1.08
Role for furin in tumor necrosis factor alpha-induced activation of the matrix metalloproteinase/sphingolipid mitogenic pathway. Mol Cell Biol (2007) 1.08
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Oxalate nephropathy associated with chronic pancreatitis. Clin J Am Soc Nephrol (2011) 1.06
Reconstitution of immunodeficient SCID/beige mice with human cells: applications in preclinical studies. Toxicology (2007) 1.05
Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic Biol Med (2008) 1.05
GFR estimation using standardized cystatin C in kidney transplant recipients. Am J Kidney Dis (2012) 1.05
Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant (2003) 1.04
A clinical scoring system highly predictive of long-term kidney graft survival. Kidney Int (2010) 1.03
Dual role of oxidized LDL on the NF-kappaB signaling pathway. Free Radic Res (2004) 1.03
p53-PGC-1α pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. Antioxid Redox Signal (2012) 1.02